18-108
141. Sam Mahoney, the CEO of Mahoney Technologies, Inc. (MTI), a biotechnology firm had
recently returned from a conference on modern cost management and performance measurement
methods where he was exposed to target costing, value-chain analysis, balanced scorecard,
activity-based management, and other ideas.
MTI is a five-year old company operating in a growing, but competitive market. It develops and
produces a number of different enzymes for use by research scientists and pharmaceutical
companies. Its main competitors are also small to medium sized firms just like MTI. The key to
growth in this industry is the ability to develop new products in a short time. Gail Stevenson, the
vice-president (VP) for research & development (R&D) has noticed that some of MTI’s new
developments did not perform well because of the delays in their introduction into the market.
Stevenson is very keen on hiring the best scientists and ensuring that they stay current in their
fields because knowledge is the key competitive weapon in the biotechnology industry.
Bob Phillips, the controller of MTI had another concern. He has been noticing that the new
products were not only delayed but their actual development costs were usually higher than
budgeted. One of his goals was to see that the new products were profitable for the company.
Linda Joseph, the production manager, had a different concern of her own. Based on her
observation, the production of the new enzymes was taking longer. Her feeling was that the
products spent too much time in the quality control (QC) department. Barry Laker, the manager of
the QC department argued that the new enzymes lacked the rigorous specifications that are
demanded in the marketplace. Consequently, the QC department has had to perform additional
tests to get to the root cause of the problems.
Mahoney had heard complaints from all quarters, and decided to convene a meeting of all the
department heads.
Mahoney: Good afternoon, everyone. I am troubled that despite hiring a number of talented
scientists, we are unable to compete effectively in the marketplace. Many of the recent entrants
in the game seem to be beating us easily.
Stevenson: Sam, the key to our growth is rapid introduction of new products. Although my
scientists are developing new enzymes in record times, they seem to be getting held up in
manufacturing and especially the QC department.
Laker: Sam, I think I can pinpoint the root cause of the problem. I agree that our scientists are
developing new enzymes in record times, but they do not seem to be paying any attention to
standards. It looks like my department will have to provide training to them regarding quality
control matters.
Stevenson: With due respect, I do not think there is more to know about QC standards. It looks
like the department wants more attention and is therefore creating all this unnecessary fuss.
Joseph: I think I will agree with Barry that there are problems at the R&D side. My production
scientists are also complaining that adequate specifications have not been developed; they have
to constantly phone their R&D counterparts for clarifications.